Skip to main content
SpringerLink
Log in

Drug Therapy and Follow-Up

  • Chapter
  • First Online:
Atherosclerosis Disease Management

  • 1195 Accesses

Abstract

Atherosclerosis is a systemic disease of the arteries and is considered the leading cause of cardiovascular diseases (CVDs), coronary artery disease (CAD), peripheral artery disease (PAD), and stroke. Atherogenesis is dramatically accelerated by the concomitant presence of major cardiovascular risk factors such as dyslipidemia, hypertension, smoking, and visceral obesity. Atherothrombosis and aneurismal disease related to atherosclerosis underlie the majority of acute cardiovascular events in developed countries.

Different pharmacological classes of drugs have been developed to treat a single specific risk factor of CVD: hipolipemic and antihypertensive agents are landmarks of antiatherogenic therapy from several years. In recent times, the development of modern imaging techniques offers new tools for documenting the effect of drugs on progression of atherosclerosis lesions. The introduction of these technologies highlights the role of surrogate end-point and biomarkers as predictors of clinical outcomes in CVDs. The potential value to public health and industries in accelerating the discovery and development processes for cardiovascular therapeutics through smaller, shorter studies, using validated endpoints other than mortality and irreversible morbidity is substantial and very attractive.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hiatt, W.R., Goldstone, J., Smith, S.C., Jr., McDermott, M., Moneta, G., Oka, R., Newman, A.B., Pearce, W.H.: Atherosclerotic peripheral vascular disease symposium II: nomenclature for vascular diseases. Circulation 118 (2008) 2826–2829

    PubMed  Google Scholar 

  2. Adams, R.J., Chimowitz, M.I., Alpert, J.S., Awad, I.A., Cerqueria, M.D., Fayad, P., Taubert, K.A.: Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 34 (2003) 2310–2322

    PubMed  Google Scholar 

  3. Kannel, W.B.: Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1 (1994) 333–339

    CAS  PubMed  Google Scholar 

  4. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229–234

    CAS  PubMed  Google Scholar 

  5. Chapman, M.J.: From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 113 (2007) 184–196

    CAS  PubMed  Google Scholar 

  6. Hopkins, P.N., Williams, R.R.: A survey of 246 suggested coronary risk factors. Atherosclerosis 40 (1981) 1–52

    CAS  PubMed  Google Scholar 

  7. Kannel, W.B., Wilson, P.W.: An update on coronary risk factors. Med Clin North Am 79 (1995) 951–971

    CAS  PubMed  Google Scholar 

  8. Third Report of the National Cholesterol Education Program (NCEP): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143–3421

    Google Scholar 

  9. Conti, C.R.: Evolution of NCEP guidelines: ATP1–ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program. Clin Cardiol 25 (2002) 89–90

    PubMed  Google Scholar 

  10. Kuhar, M.B.: Update on managing hypercholesterolemia. The new NCEP guidelines. AAOHN J 50 (2002) 360–364

    PubMed  Google Scholar 

  11. Smith, S.C., Jr., Allen, J., Blair, S.N., Bonow, R.O., Brass, L.M., Fonarow, G.C., Grundy, S.M., Hiratzka, L., Jones, D., Krumholz, H.M., Mosca, L., Pearson, T., Pfeffer, M.A., Taubert, K.A.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 (2006) 2130–2139

    PubMed  Google Scholar 

  12. Segura, J., Ruilope, L.M.: New guidelines of the European Society of Hypertension. Curr Hypertens Rep 10 (2008) 337–338

    PubMed  Google Scholar 

  13. Marzolo, M., Verlato, F., Zotta, L., Guadagnin, M.L., Borgese, L., Cravatari, M., Nardi, M., Camporese, G., Andreozzi, G.M.: Occult atherosclerosis and physical vascular examination: a simple strategy to avoid inadequate cardiovascular prevention and under-use of diagnostic vascular guidelines in outpatients. A multicenter study by Angiology Care Units in North-Eastern Italy. Int Angiol 27 (2008) 426–432

    CAS  PubMed  Google Scholar 

  14. Gidding, S.S., Lichtenstein, A.H., Faith, M.S., Karpyn, A., Mennella, J.A., Popkin, B., Rowe, J., Van Horn, L., Whitsel, L.: Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 119 (2009) 1161–1175

    PubMed  Google Scholar 

  15. de la Sierra, A., Zamorano, J.L., Ruilope, L.M.: Application of hypertension guidelines in clinical practice: implementation of the 2007 ESH/ESC European practice Guidelines in Spain. J Hypertens 27 Suppl 3 (2009) S27–S32

    Google Scholar 

  16. Smith, S.C., Jr., Jackson, R., Pearson, T.A., Fuster, V., Yusuf, S., Faergeman, O., Wood, D.A., Alderman, M., Horgan, J., Home, P., Hunn, M., Grundy, S.M.: Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 109 (2004) 3112–3121

    PubMed  Google Scholar 

  17. Munger, M.A., Hawkins, D.W.: Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (2003) 44 (2004) S5–S12; quiz S12–S13

    Google Scholar 

  18. Libby, P., Theroux, P.: Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481–3488

    PubMed  Google Scholar 

  19. Libby, P.: Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 98 (2006) 3Q–9Q

    CAS  PubMed  Google Scholar 

  20. Libby, P.: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83 (2006) 456S–460S

    CAS  PubMed  Google Scholar 

  21. Libby, P.: Inflammation in atherosclerosis. Nature 420 (2002) 868–874

    CAS  PubMed  Google Scholar 

  22. Libby, P., Ridker, P.M., Hansson, G.K.: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54 (2009) 2129–2138

    CAS  PubMed  Google Scholar 

  23. Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., Fayad, Z., Stone, P.H., Waxman, S., Raggi, P., Madjid, M., Zarrabi, A., Burke, A., Yuan, C., Fitzgerald, P.J., Siscovick, D.S., de Korte, C.L., Aikawa, M., Juhani, K.E., Assmann, G., Becker, C.R., Chesebro, J.H., Farb, A., Galis, Z.S., Jackson, C., Jang, I.K., Koenig, W., Lodder, R.A., March, K., Demirovic, J., Navab, M., Priori, S.G., Rekhter, M.D., Bahr, R., Grundy, S.M., Mehran, R., Colombo, A., Boerwinkle, E., Ballantyne, C., Insull, W., Jr., Schwartz, R.S., Vogel, R., Serruys, P.W., Hansson, G.K., Faxon, D.P., Kaul, S., Drexler, H., Greenland, P., Muller, J.E., Virmani, R., Ridker, P.M., Zipes, D.P., Shah, P.K., Willerson, J.T.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108 (2003) 1664–1672

    PubMed  Google Scholar 

  24. Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., Fayad, Z., Stone, P.H., Waxman, S., Raggi, P., Madjid, M., Zarrabi, A., Burke, A., Yuan, C., Fitzgerald, P.J., Siscovick, D.S., de Korte, C.L., Aikawa, M., Airaksinen, K.E., Assmann, G., Becker, C.R., Chesebro, J.H., Farb, A., Galis, Z.S., Jackson, C., Jang, I.K., Koenig, W., Lodder, R.A., March, K., Demirovic, J., Navab, M., Priori, S.G., Rekhter, M.D., Bahr, R., Grundy, S.M., Mehran, R., Colombo, A., Boerwinkle, E., Ballantyne, C., Insull, W., Jr., Schwartz, R.S., Vogel, R., Serruys, P.W., Hansson, G.K., Faxon, D.P., Kaul, S., Drexler, H., Greenland, P., Muller, J.E., Virmani, R., Ridker, P.M., Zipes, D.P., Shah, P.K., Willerson, J.T.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108 (2003) 1772–1778

    PubMed  Google Scholar 

  25. Hadi, H.A., Carr, C.S., Al Suwaidi, J.: Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1 (2005) 183–198

    CAS  PubMed  Google Scholar 

  26. Anderson, T.J., Gerhard, M.D., Meredith, I.T., Charbonneau, F., Delagrange, D., Creager, M.A., Selwyn, A.P., Ganz, P.: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75 (1995) 71B–74B

    CAS  PubMed  Google Scholar 

  27. Kinlay, S., Ganz, P.: Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol 80 (1997) 11I–16I

    CAS  PubMed  Google Scholar 

  28. Traub, O., Berk, B.C.: Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18 (1998) 677–685

    CAS  PubMed  Google Scholar 

  29. Libby, P., Ridker, P.M., Maseri, A.: Inflammation and atherosclerosis. Circulation 105 (2002) 1135–1143

    CAS  PubMed  Google Scholar 

  30. Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller, O.I., Sullivan, I.D., Lloyd, J.K., Deanfield, J.E.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111–1115

    CAS  PubMed  Google Scholar 

  31. Prasad, A., Zhu, J., Halcox, J.P., Waclawiw, M.A., Epstein, S.E., Quyyumi, A.A.: Predis­position to atherosclerosis by infections: role of endothelial dysfunction. Circulation 106 (2002) 184–190

    PubMed  Google Scholar 

  32. Steinberg, H.O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., Baron, A.D.: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601–2610

    CAS  PubMed  Google Scholar 

  33. Thogersen, A.M., Jansson, J.H., Boman, K., Nilsson, T.K., Weinehall, L., Huhtasaari, F., Hallmans, G.: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241–2247

    CAS  PubMed  Google Scholar 

  34. Al Suwaidi, J., Higano, S.T., Holmes, D.R., Jr., Lennon, R., Lerman, A.: Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37 (2001) 1523–1528

    CAS  PubMed  Google Scholar 

  35. Fichtlscherer, S., Zeiher, A.M.: Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann Med 32 (2000) 515–518

    CAS  PubMed  Google Scholar 

  36. Fichtlscherer, S., Rosenberger, G., Walter, D.H., Breuer, S., Dimmeler, S., Zeiher, A.M.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 (2000) 1000–1006

    CAS  PubMed  Google Scholar 

  37. Bonetti, P.O., Lerman, L.O., Lerman, A.: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23 (2003) 168–175

    CAS  PubMed  Google Scholar 

  38. Lum, H., Roebuck, K.A.: Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 280 (2001) C719–C741

    CAS  PubMed  Google Scholar 

  39. Deanfield, J., Donald, A., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., Mancia, G., Oliver, J.J., Pessina, A.C., Rizzoni, D., Rossi, G.P., Salvetti, A., Schiffrin, E.L., Taddei, S., Webb, D.J.: Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertens 23 (2005) 7–17

    CAS  PubMed  Google Scholar 

  40. Wilson, P.W., D’Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B.: Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837–1847

    CAS  PubMed  Google Scholar 

  41. Stamler, J., Wentworth, D., Neaton, J.D.: Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med 80 (1986) 33–39

    CAS  PubMed  Google Scholar 

  42. Rifkind, B.M.: Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am J Cardiol 54 (1984) 30C–34C

    CAS  PubMed  Google Scholar 

  43. Rossouw, J.E., Lewis, B., Rifkind, B.M.: The value of lowering cholesterol after myocardial infarction. N Engl J Med 323 (1990) 1112–1119

    CAS  PubMed  Google Scholar 

  44. Law, M.R., Wald, N.J., Rudnicka, A.R.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423

    CAS  PubMed  Google Scholar 

  45. Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B., Jr., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C., Jr., Stone, N.J.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227–239

    PubMed  Google Scholar 

  46. Brown, W.V.: Cholesterol lowering in atherosclerosis. Am J Cardiol 86 (2000) 29H–32H

    CAS  PubMed  Google Scholar 

  47. Forrester, J.S., Shah, P.K.: Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 98 (2006) 1542–1549

    CAS  PubMed  Google Scholar 

  48. Vega, G.L., Grundy, S.M.: Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 7 (1996) 209–216

    CAS  PubMed  Google Scholar 

  49. Tall, A.R.: An overview of reverse cholesterol transport. Eur Heart J 19 Suppl A (1998) A31–A35

    CAS  PubMed  Google Scholar 

  50. Tall, A.R.: Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263 (2008) 256–273

    CAS  PubMed  Google Scholar 

  51. Tedgui, A., Mallat, Z.: Anti-inflammatory mechanisms in the vascular wall. Circ Res 88 (2001) 877–887

    CAS  PubMed  Google Scholar 

  52. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., Evans, R.M.: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241–252

    CAS  PubMed  Google Scholar 

  53. Tedgui, A., Mallat, Z.: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 86 (2001) 420–426

    CAS  PubMed  Google Scholar 

  54. Hansson, G.K.: Atherosclerosis – an immune disease: the Anitschkov lecture 2007. Ather­osclerosis 202 (2009) 2–10

    CAS  PubMed  Google Scholar 

  55. Sposito, A.C., Chapman, M.J.: Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 22 (2002) 1524–1534

    CAS  PubMed  Google Scholar 

  56. Tedgui, A., Mallat, Z.: Apoptosis, a major determinant of atherothrombosis. Arch Mal Coeur Vaiss 96 (2003) 671–675

    CAS  PubMed  Google Scholar 

  57. Greenland, P., Abrams, J., Aurigemma, G.P., Bond, M.G., Clark, L.T., Criqui, M.H., Crouse, J.R., 3rd, Friedman, L., Fuster, V., Herrington, D.M., Kuller, L.H., Ridker, P.M., Roberts, W.C., Stanford, W., Stone, N., Swan, H.J., Taubert, K.A., Wexler, L.: Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 101 (2000) E16–E22

    CAS  PubMed  Google Scholar 

  58. Detrano, R.C.: Coronary artery scanning using electron beam computed tomography. Am J Card Imaging 10 (1996) 97–100

    CAS  PubMed  Google Scholar 

  59. Detrano, R.C., Wong, N.D., Doherty, T.M., Shavelle, R.M., Tang, W., Ginzton, L.E., Budoff, M.J., Narahara, K.A.: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation 99 (1999) 2633–2638

    CAS  PubMed  Google Scholar 

  60. Raggi, P.: Regression of calcified coronary artery plaque assessed by electron beam ­computed tomography. Z Kardiol 89 Suppl 2 (2000) 135–139

    PubMed  Google Scholar 

  61. O’Malley, P.G., Taylor, A.J., Jackson, J.L., Doherty, T.M., Detrano, R.C.: Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 85 (2000) 945–948

    PubMed  Google Scholar 

  62. O’Rourke, R.A., Brundage, B.H., Froelicher, V.F., Greenland, P., Grundy, S.M., Hachamovitch, R., Pohost, G.M., Shaw, L.J., Weintraub, W.S., Winters, W.L., Jr., Forrester, J.S., Douglas, P.S., Faxon, D.P., Fisher, J.D., Gregoratos, G., Hochman, J.S., Hutter, A.M., Jr., Kaul, S., Wolk, M.J.: American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102 (2000) 126–140

    PubMed  Google Scholar 

  63. Grundy, S.M.: Age as a risk factor: you are as old as your arteries. Am J Cardiol 83 (1999) 1455–1457; A1457

    CAS  PubMed  Google Scholar 

  64. Boissel, J.P., Collet, J.P., Moleur, P., Haugh, M.: Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 43 (1992) 235–244

    CAS  PubMed  Google Scholar 

  65. Espeland, M.A., O’Leary D, H., Terry, J.G., Morgan, T., Evans, G., Mudra, H.: Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6 (2005) 3

    PubMed  Google Scholar 

  66. Mitchell, J.R., Schwartz, C.J.: Relationship between arterial disease in different sites. A study of the aorta and coronary, carotid, and iliac arteries. Br Med J 1 (1962) 1293–1301

    CAS  PubMed  Google Scholar 

  67. Wofford, J.L., Kahl, F.R., Howard, G.R., McKinney, W.M., Toole, J.F., Crouse, J.R., 3rd: Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 11 (1991) 1786–1794

    CAS  PubMed  Google Scholar 

  68. Dormandy, J., Heeck, L., Vig, S.: Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg 12 (1999) 118–122

    CAS  PubMed  Google Scholar 

  69. Revkin, J.H., Shear, C.L., Pouleur, H.G., Ryder, S.W., Orloff, D.G.: Biomarkers in the ­prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev 59 (2007) 40–53

    CAS  PubMed  Google Scholar 

  70. Rossouw, J.E.: Lipid-lowering interventions in angiographic trials. Am J Cardiol 76 (1995) 86C–92C

    CAS  PubMed  Google Scholar 

  71. Smith, S.C., Jr., Blair, S.N., Criqui, M.H., Fletcher, G.F., Fuster, V., Gersh, B.J., Gotto, A.M., Gould, K.L., Greenland, P., Grundy, S.M., Hill, M.N., Hlatky, M.A., Houston-Miller, N., Krauss, R.M., LaRosa, J., Ockene, I.S., Oparil, S., Pearson, T.A., Rapaport, E., Starke, R.D.: Preventing heart attack and death in patients with coronary disease. Endorsed by the board of trustees of the American College of Cardiology. Cardiovasc Nurs 32 (1996) 26–28

    PubMed  Google Scholar 

  72. Simon, A., Gariepy, J., Chironi, G., Megnien, J.L., Levenson, J.: Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 20 (2002) 159–169

    CAS  PubMed  Google Scholar 

  73. Duivenvoorden, R., Nederveen, A.J., de Groot, E., Kastelein, J.J.: Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 18 (2007) 613–621

    CAS  PubMed  Google Scholar 

  74. Prati, F., Arbustini, E., Labellarte, A., Dal Bello, B., Sommariva, L., Mallus, M.T., Pagano, A., Boccanelli, A.: Correlation between high frequency intravascular ultrasound and histomorphology in human coronary arteries. Heart 85 (2001) 567–570

    CAS  PubMed  Google Scholar 

  75. Tuzcu, E.M., Kapadia, S.R., Tutar, E., Ziada, K.M., Hobbs, R.E., McCarthy, P.M., Young, J.B., Nissen, S.E.: High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103 (2001) 2705–2710

    CAS  PubMed  Google Scholar 

  76. von Birgelen, C., Hartmann, M., Mintz, G.S., van Houwelingen, K.G., Deppermann, N., Schmermund, A., Bose, D., Eggebrecht, H., Neumann, T., Gossl, M., Wieneke, H., Erbel, R.: Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 (2004) 1579–1585

    Google Scholar 

  77. Hertog, M.G.: Workshop on CV prevention with a focus on metabolic syndrome and surrogate markers. Taskforce 1 of the Cardiovascular Round Table, European Society of Cardiology: Executive Summary Report. Eur Heart J 27 (2006) 114–115

    PubMed  Google Scholar 

  78. Fayad, Z.A., Nahar, T., Fallon, J.T., Goldman, M., Aguinaldo, J.G., Badimon, J.J., Shinnar, M., Chesebro, J.H., Fuster, V.: In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101 (2000) 2503–2509

    CAS  PubMed  Google Scholar 

  79. Fayad, Z.A., Fuster, V.: Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann N Y Acad Sci 902 (2000) 173–186

    CAS  PubMed  Google Scholar 

  80. Momiyama, Y., Kato, R., Fayad, Z.A., Tanaka, N., Taniguchi, H., Ohmori, R., Kihara, T., Kameyama, A., Miyazaki, K., Kimura, K., Arakawa, K., Kusuhara, M., Nagata, M., Nakamura, H., Ohsuzu, F.: A possible association between coronary plaque instability and complex plaques in abdominal aorta. Arterioscler Thromb Vasc Biol 26 (2006) 903–909

    CAS  PubMed  Google Scholar 

  81. Lima, J.A., Desai, M.Y., Steen, H., Warren, W.P., Gautam, S., Lai, S.: Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336–2341

    CAS  PubMed  Google Scholar 

  82. Wiviott, S.D., Cannon, C.P.: Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med 3 (2006) 424–436

    CAS  PubMed  Google Scholar 

  83. Smith, E.E., Abdullah, A.R., Amirfarzan, H., Schwamm, L.H.: Serum lipid profile on admission for ischemic stroke: failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Neurology 68 (2007) 660–665

    CAS  PubMed  Google Scholar 

  84. Singh, V., Deedwania, P.: Reducing morbidity and mortality in high risk patients with statins. Vasc Health Risk Manag 5 (2009) 495–507

    CAS  PubMed  Google Scholar 

  85. Kent, S.M., Coyle, L.C., Flaherty, P.J., Markwood, T.T., Taylor, A.J.: Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis. Clin Cardiol 27 (2004) 17–21

    PubMed  Google Scholar 

  86. Endo, A.: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 (1992) 1569–1582

    CAS  PubMed  Google Scholar 

  87. Vega, G.L., Grundy, S.M.: Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 150 (1990) 1313–1319

    CAS  PubMed  Google Scholar 

  88. Broyles, F.E., Walden, C.E., Hunninghake, D.B., Hill-Williams, D., Knopp, R.H.: Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 76 (1995) 129A–135A

    CAS  PubMed  Google Scholar 

  89. Bakker-Arkema, R.G., Davidson, M.H., Goldstein, R.J., Davignon, J., Isaacsohn, J.L., Weiss, S.R., Keilson, L.M., Brown, W.V., Miller, V.T., Shurzinske, L.J., Black, D.M.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275 (1996) 128–133

    CAS  PubMed  Google Scholar 

  90. Arad, Y., Ramakrishnan, R., Ginsberg, H.N.: Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41 (1992) 487–493

    CAS  PubMed  Google Scholar 

  91. Twisk, J., Gillian-Daniel, D.L., Tebon, A., Wang, L., Barrett, P.H., Attie, A.D.: The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest 105 (2000) 521–532

    CAS  PubMed  Google Scholar 

  92. Stein, E.A., Lane, M., Laskarzewski, P.: Comparison of statins in hypertriglyceridemia. Am J Cardiol 81 (1998) 66B–69B

    CAS  PubMed  Google Scholar 

  93. Jones, P., Kafonek, S., Laurora, I., Hunninghake, D.: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582–587

    CAS  PubMed  Google Scholar 

  94. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., Davis, B.R., Braunwald, E.: The effect of pravastatin on coronary events after myocardial infarction in patients with average ­cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001–1009

    CAS  PubMed  Google Scholar 

  95. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349–1357

    Google Scholar 

  96. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M., Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615–1622

    CAS  PubMed  Google Scholar 

  97. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383–1389

    Google Scholar 

  98. LaRosa, J.C., He, J., Vupputuri, S.: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340–2346

    CAS  PubMed  Google Scholar 

  99. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., Packard, C.J.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301–1307

    CAS  PubMed  Google Scholar 

  100. Maron, D.J., Fazio, S., Linton, M.F.: Current perspectives on statins. Circulation 101 (2000) 207–213

    CAS  PubMed  Google Scholar 

  101. Pyorala, K., Pedersen, T.R., Kjekshus, J., Faergeman, O., Olsson, A.G., Thorgeirsson, G.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614–620

    CAS  PubMed  Google Scholar 

  102. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 336 (1997) 153–162

    Google Scholar 

  103. Knatterud, G.L., Rosenberg, Y., Campeau, L., Geller, N.L., Hunninghake, D.B., Forman, S.A., Forrester, J.S., Gobel, F.L., Herd, J.A., Hickey, A., Hoogwerf, B.J., Terrin, M.L., White, C.: Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 102 (2000) 157–165

    CAS  PubMed  Google Scholar 

  104. Blankenhorn, D.H., Azen, S.P., Kramsch, D.M., Mack, W.J., Cashin-Hemphill, L., Hodis, H.N., DeBoer, L.W., Mahrer, P.R., Masteller, M.J., Vailas, L.I., Alaupovic, P., Hirsch, L.J.: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119 (1993) 969–976

    CAS  PubMed  Google Scholar 

  105. Kroon, A.A., Aengevaeren, W.R., van der Werf, T., Uijen, G.J., Reiber, J.H., Bruschke, A.V., Stalenhoef, A.F.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93 (1996) 1826–1835

    CAS  PubMed  Google Scholar 

  106. Pitt, B., Waters, D., Brown, W.V., van Boven, A.J., Schwartz, L., Title, L.M., Eisenberg, D., Shurzinske, L., McCormick, L.S.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341 (1999) 70–76

    CAS  PubMed  Google Scholar 

  107. Brown, W.V.: The benefit of aggressive lipid lowering. Atheroscler Suppl 1 (2000) 15–19

    CAS  PubMed  Google Scholar 

  108. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A., Chaitman, B.R., Leslie, S., Stern, T.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711–1718

    CAS  PubMed  Google Scholar 

  109. Stenestrand, U., Wallentin, L.: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430–436

    CAS  PubMed  Google Scholar 

  110. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348 (1996) 1339–1342

    Google Scholar 

  111. Ballantyne, C.M., Herd, J.A., Dunn, J.K., Jones, P.H., Farmer, J.A., Gotto, A.M., Jr.: Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 8 (1997) 354–361

    CAS  PubMed  Google Scholar 

  112. Brown, B.G., Zhao, X.Q.: Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol 82 (1998) 49T–52T

    CAS  PubMed  Google Scholar 

  113. Buchwald, H., Varco, R.L., Matts, J.P., Long, J.M., Fitch, L.L., Campbell, G.S., Pearce, M.B., Yellin, A.E., Edmiston, W.A., Smink, R.D., Jr., et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323 (1990) 946–955

    CAS  PubMed  Google Scholar 

  114. Brown, B.G., Zhao, X.Q., Sacco, D.E., Albers, J.J.: Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 69 (1993) S48–S53

    CAS  PubMed  Google Scholar 

  115. Furberg, C.D., Adams, H.P., Jr., Applegate, W.B., Byington, R.P., Espeland, M.A., Hartwell, T., Hunninghake, D.B., Lefkowitz, D.S., Probstfield, J., Riley, W.A., et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90 (1994) 1679–1687

    CAS  PubMed  Google Scholar 

  116. Salonen, R., Nyyssonen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.S., Salonen, J.T.: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 (1995) 1758–1764

    CAS  PubMed  Google Scholar 

  117. Crouse, J.R., 3rd, Byington, R.P., Bond, M.G., Espeland, M.A., Craven, T.E., Sprinkle, J.W., McGovern, M.E., Furberg, C.D.: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 75 (1995) 455–459

    PubMed  Google Scholar 

  118. Salonen, R., Nyssonen, K., Porkkala-Sarataho, E., Salonen, J.T.: The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 76 (1995) 34C–39C

    CAS  PubMed  Google Scholar 

  119. Mercuri, M., Bond, M.G., Sirtori, C.R., Veglia, F., Crepaldi, G., Feruglio, F.S., Descovich, G., Ricci, G., Rubba, P., Mancini, M., Gallus, G., Bianchi, G., D’Alo, G., Ventura, A.: Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101 (1996) 627–634

    CAS  PubMed  Google Scholar 

  120. de Groot, E., Jukema, J.W., Montauban van Swijndregt, A.D., Zwinderman, A.H., Ackerstaff, R.G., van der Steen, A.F., Bom, N., Lie, K.I., Bruschke, A.V.: B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 31 (1998) 1561–1567

    PubMed  Google Scholar 

  121. Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., Berglund, G.: Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103 (2001) 1721–1726

    CAS  PubMed  Google Scholar 

  122. Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., Hayashi, J.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39 (2002) 610–616

    CAS  PubMed  Google Scholar 

  123. Al Badarin, F.J., Kullo, I.J., Kopecky, S.L., Thomas, R.J.: Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc 84 (2009) 353–361

    CAS  PubMed  Google Scholar 

  124. Nolting, P.R., de Groot, E., Zwinderman, A.H., Buirma, R.J., Trip, M.D., Kastelein, J.J.: Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 163 (2003) 1837–1841

    PubMed  Google Scholar 

  125. Kastelein, J.J., Akdim, F., Stroes, E.S., Zwinderman, A.H., Bots, M.L., Stalenhoef, A.F., Visseren, F.L., Sijbrands, E.J., Trip, M.D., Stein, E.A., Gaudet, D., Duivenvoorden, R., Veltri, E.P., Marais, A.D., de Groot, E.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431–1443

    CAS  PubMed  Google Scholar 

  126. Smilde, T.J., van Wissen, S., Wollersheim, H., Trip, M.D., Kastelein, J.J., Stalenhoef, A.F.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577–581

    CAS  PubMed  Google Scholar 

  127. Taylor, A.J., Kent, S.M., Flaherty, P.J., Coyle, L.C., Markwood, T.T., Vernalis, M.N.: ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055–2060

    CAS  PubMed  Google Scholar 

  128. Crouse, J.R., 3rd, Raichlen, J.S., Riley, W.A., Evans, G.W., Palmer, M.K., O’Leary, D.H., Grobbee, D.E., Bots, M.L.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297 (2007) 1344–1353

    CAS  PubMed  Google Scholar 

  129. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., McQuay, H.J.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 (1996) 1–12

    CAS  PubMed  Google Scholar 

  130. Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., Davignon, J., Erbel, R., Fruchart, J.C., Tardif, J.C., Schoenhagen, P., Crowe, T., Cain, V., Wolski, K., Goormastic, M., Tuzcu, E.M.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556–1565

    CAS  PubMed  Google Scholar 

  131. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., Crowe, T., Howard, G., Cooper, C.J., Brodie, B., Grines, C.L., DeMaria, A.N.: Effect of intensive ­compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071–1080

    CAS  PubMed  Google Scholar 

  132. Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H., Daida, H.: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110 (2004) 1061–1068

    CAS  PubMed  Google Scholar 

  133. Takagi, T., Yoshida, K., Akasaka, T., Hozumi, T., Morioka, S., Yoshikawa, J.: Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 79 (1997) 1673–1676

    CAS  PubMed  Google Scholar 

  134. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A., Skene, A.M.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495–1504

    CAS  PubMed  Google Scholar 

  135. Yonemura, A., Momiyama, Y., Fayad, Z.A., Ayaori, M., Ohmori, R., Higashi, K., Kihara, T., Sawada, S., Iwamoto, N., Ogura, M., Taniguchi, H., Kusuhara, M., Nagata, M., Nakamura, H., Tamai, S., Ohsuzu, F.: Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733–742

    CAS  PubMed  Google Scholar 

  136. Ayaori, M., Momiyama, Y., Fayad, Z.A., Yonemura, A., Ohmori, R., Kihara, T., Tanaka, N., Nakaya, K., Ogura, M., Sawada, S., Taniguchi, H., Kusuhara, M., Nagata, M., Nakamura, H., Ohsuzu, F.: Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 196 (2008) 425–433

    CAS  PubMed  Google Scholar 

  137. Corti, R., Fuster, V., Fayad, Z.A., Worthley, S.G., Helft, G., Smith, D., Weinberger, J., Wentzel, J., Mizsei, G., Mercuri, M., Badimon, J.J.: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884–2887

    CAS  PubMed  Google Scholar 

  138. Yonemura, A., Momiyama, Y., Fayad, Z.A., Ayaori, M., Ohmori, R., Kihara, T., Tanaka, N., Nakaya, K., Ogura, M., Taniguchi, H., Kusuhara, M., Nagata, M., Nakamura, H., Tamai, S., Ohsuzu, F.: Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI. Eur J Cardiovasc Prev Rehabil 16 (2009) 222–228

    PubMed  Google Scholar 

  139. Liao, J.K.: Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86 (2002) 5–18

    PubMed  Google Scholar 

  140. Nilsson, J.: Nobel seminar: molecular medicine – cell biology in disease. The mevalonate pathway – a link between cellular cholesterol homeostasis and growth regulation. J Intern Med 232 (1992) 10–13

    CAS  PubMed  Google Scholar 

  141. Takemoto, M., Liao, J.K.: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712–1719

    CAS  PubMed  Google Scholar 

  142. Rikitake, Y., Liao, J.K.: Rho GTPases, statins, and nitric oxide. Circ Res 97 (2005) 1232–1235

    CAS  PubMed  Google Scholar 

  143. Laufs, U., Wassmann, S., Hilgers, S., Ribaudo, N., Bohm, M., Nickenig, G.: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88 (2001) 1306–1307

    CAS  PubMed  Google Scholar 

  144. Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., Hommel, U.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687–692

    CAS  PubMed  Google Scholar 

  145. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., Cook, N.R.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557–1565

    CAS  PubMed  Google Scholar 

  146. Kayikcioglu, M., Can, L., Evrengul, H., Payzin, S., Kultursay, H.: The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 90 (2003) 63–72

    PubMed  Google Scholar 

  147. Young-Xu, Y., Jabbour, S., Goldberg, R., Blatt, C.M., Graboys, T., Bilchik, B., Ravid, S.: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379–1383

    CAS  PubMed  Google Scholar 

  148. Aronow, W.S., Ahn, C.: Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 147–149

    CAS  PubMed  Google Scholar 

  149. Node, K., Fujita, M., Kitakaze, M., Hori, M., Liao, J.K.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839–843

    CAS  PubMed  Google Scholar 

  150. Hebert, P.R., Gaziano, J.M., Chan, K.S., Hennekens, C.H.: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313–321

    CAS  PubMed  Google Scholar 

  151. Corvol, J.C., Bouzamondo, A., Sirol, M., Hulot, J.S., Sanchez, P., Lechat, P.: Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 163 (2003) 669–676

    CAS  PubMed  Google Scholar 

  152. Freeman, D.J., Norrie, J., Sattar, N., Neely, R.D., Cobbe, S.M., Ford, I., Isles, C., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H., Packard, C.J., Shepherd, J., Gaw, A.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357–362

    CAS  PubMed  Google Scholar 

  153. Crisby, M., Carlson, L.A., Winblad, B.: Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 16 (2002) 131–136

    CAS  PubMed  Google Scholar 

  154. Kirsch, C., Eckert, G.P., Mueller, W.E.: Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65 (2003) 843–856

    CAS  PubMed  Google Scholar 

  155. Leung, B.P., Sattar, N., Crilly, A., Prach, M., McCarey, D.W., Payne, H., Madhok, R., Campbell, C., Gracie, J.A., Liew, F.Y., McInnes, I.B.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170 (2003) 1524–1530

    CAS  PubMed  Google Scholar 

  156. Wong, R.W., Rabie, A.B.: Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg 41 (2003) 244–248

    CAS  PubMed  Google Scholar 

  157. Meroni, P.L., Raschi, E., Testoni, C., Tincani, A., Balestrieri, G.: Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am 27 (2001) 587–602

    CAS  PubMed  Google Scholar 

  158. van de Donk, N.W., Kamphuis, M.M., Lokhorst, H.M., Bloem, A.C.: The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16 (2002) 1362–1371

    PubMed  Google Scholar 

  159. Neuhaus, O., Archelos, J.J., Hartung, H.P.: Statins in multiple sclerosis: a new therapeutic option? Mult Scler 9 (2003) 429–430

    CAS  PubMed  Google Scholar 

  160. Gould, A.L., Cariski, A.T.: Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators. Ann Surg 227 (1998) 314–316

    CAS  PubMed  Google Scholar 

  161. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346 (1995) 1647–1653

    Google Scholar 

  162. Dechend, R., Fiebler, A., Lindschau, C., Bischoff, H., Muller, D., Park, J.K., Dietz, R., Haller, H., Luft, F.C.: Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 14 (2001) 55S–61S

    CAS  PubMed  Google Scholar 

  163. Sarkar, K., Sinha, A.K., Mehta, J.L.: The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 21 (2006) 316–321

    PubMed  Google Scholar 

  164. Davignon, J.: Emphasis on pleiotropic effects, a new paradigm shift? [Review]. Coron Artery Dis 15 (2004) 223–225

    PubMed  Google Scholar 

  165. Venkatesh, P.K.M., Caskey, D.M., Reddy, P.C.M.: Therapies to increase high-density ­lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. Am J Med Sci 336 (2008) 64–68

    PubMed  Google Scholar 

  166. Eisenberg, S., Gavish, D., Oschry, Y., Fainaru, M., Deckelbaum, R.J.: Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 74 (1984) 470–482

    CAS  PubMed  Google Scholar 

  167. Schoonjans, K., Staels, B., Auwerx, J.: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907–925

    CAS  PubMed  Google Scholar 

  168. Fruchart, J.C., Brewer, H.B., Jr., Leitersdorf, E.: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 81 (1998) 912–917

    CAS  PubMed  Google Scholar 

  169. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.C., Staels, B., Auwerx, J.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96 (1995) 741–750

    CAS  PubMed  Google Scholar 

  170. Neve, B.P., Fruchart, J.C., Staels, B.: Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60 (2000) 1245–1250

    CAS  PubMed  Google Scholar 

  171. Pineda Torra, I., Gervois, P., Staels, B.: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10 (1999) 151–159

    CAS  PubMed  Google Scholar 

  172. Pauciullo, P., Marotta, G., Rubba, P., Cortese, C., Caruso, M.G., Gnasso, A., Fischetti, A., Motti, C., Mancini, M.: Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia. J Intern Med 228 (1990) 425–430

    CAS  PubMed  Google Scholar 

  173. Leaf, D.A., Connor, W.E., Illingworth, D.R., Bacon, S.P., Sexton, G.: The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA 262 (1989) 3154–3160

    CAS  PubMed  Google Scholar 

  174. Kornitzer, M., Dramaix, M., Vandenbroek, M.D., Everaert, L., Gerlinger, C.: Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis 110 Suppl (1994) S49–S54

    CAS  PubMed  Google Scholar 

  175. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40 (1978) 1069–1118

    Google Scholar 

  176. Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237–1245

    CAS  PubMed  Google Scholar 

  177. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360–381

    Google Scholar 

  178. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J 4 (1971) 767–775

    Google Scholar 

  179. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J 4 (1971) 775–784

    Google Scholar 

  180. Carlson, L.A., Rosenhamer, G.: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405–418

    CAS  PubMed  Google Scholar 

  181. Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T.J., Wittes, J.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410–418

    CAS  PubMed  Google Scholar 

  182. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21–27

    Google Scholar 

  183. Huttunen, J.K., Heinonen, O.P., Manninen, V., Koskinen, P., Hakulinen, T., Teppo, L., Manttari, M., Frick, M.H.: The Helsinki Heart Study: an 8.5-year safety and mortality ­follow-up. J Intern Med 235 (1994) 31–39

    CAS  PubMed  Google Scholar 

  184. Kamanna, V.S., Kashyap, M.L.: Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 100 (2007) S53–S61

    PubMed  Google Scholar 

  185. Vega, G.L., Grundy, S.M.: Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 154 (1994) 73–82

    CAS  PubMed  Google Scholar 

  186. Luria, M.H.: Effect of low-dose niacin on high-density lipoprotein cholesterol and total ­cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 148 (1988) 2493–2495

    CAS  PubMed  Google Scholar 

  187. McKenney, J.M., Proctor, J.D., Harris, S., Chinchili, V.M.: A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 271 (1994) 672–677

    CAS  PubMed  Google Scholar 

  188. Illingworth, D.R., Stein, E.A., Mitchel, Y.B., Dujovne, C.A., Frost, P.H., Knopp, R.H., Tun, P., Zupkis, R.V., Greguski, R.A.: Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154 (1994) 1586–1595

    CAS  PubMed  Google Scholar 

  189. Canner, P.L., Berge, K.G., Wenger, N.K., Stamler, J., Friedman, L., Prineas, R.J., Friedewald, W.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245–1255

    CAS  PubMed  Google Scholar 

  190. Blankenhorn, D.H., Nessim, S.A., Johnson, R.L., Sanmarco, M.E., Azen, S.P., Cashin-Hemphill, L.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233–3240

    CAS  PubMed  Google Scholar 

  191. Brown, G., Albers, J.J., Fisher, L.D., Schaefer, S.M., Lin, J.T., Kaplan, C., Zhao, X.Q., Bisson, B.D., Fitzpatrick, V.F., Dodge, H.T.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289–1298

    CAS  PubMed  Google Scholar 

  192. Brown, B.G., Zhao, X.Q., Chait, A., Fisher, L.D., Cheung, M.C., Morse, J.S., Dowdy, A.A., Marino, E.K., Bolson, E.L., Alaupovic, P., Frohlich, J., Albers, J.J.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583–1592

    CAS  PubMed  Google Scholar 

  193. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in ­incidence of coronary heart disease. JAMA 251 (1984) 351–364

    Google Scholar 

  194. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of ­reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365–374

    Google Scholar 

  195. Hamilton, P.: Role of ezetimibe in the management of patients with atherosclerosis. Coron Artery Dis 20 (2009) 169–174

    PubMed  Google Scholar 

  196. Bays, H.E., Moore, P.B., Drehobl, M.A., Rosenblatt, S., Toth, P.D., Dujovne, C.A., Knopp, R.H., Lipka, L.J., Lebeaut, A.P., Yang, B., Mellars, L.E., Cuffie-Jackson, C., Veltri, E.P.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23 (2001) 1209–1230

    CAS  PubMed  Google Scholar 

  197. Knopp, R.H., Dujovne, C.A., Le Beaut, A., Lipka, L.J., Suresh, R., Veltri, E.P.: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 57 (2003) 363–368

    CAS  PubMed  Google Scholar 

  198. Melani, L., Mills, R., Hassman, D., Lipetz, R., Lipka, L., LeBeaut, A., Suresh, R., Mukhopadhyay, P., Veltri, E.: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24 (2003) 717–728

    CAS  PubMed  Google Scholar 

  199. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903–1913

    PubMed  Google Scholar 

  200. Jacoby, D.S., Rader, D.J.: Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 163 (2003) 1155–1164

    CAS  PubMed  Google Scholar 

  201. Schmitz, G., Hankowitz, J., Kovacs, E.M.: Cellular processes in atherogenesis: potential targets of Ca2+ channel blockers. Atherosclerosis 88 (1991) 109–132

    CAS  PubMed  Google Scholar 

  202. Tulenko, T.N., Laury-Kleintop, L., Walter, M.F., Mason, R.P.: Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 62 Suppl 2 (1997) S55–S66

    PubMed  Google Scholar 

  203. Ruilope, L.M., Rosei, E.A., Bakris, G.L., Mancia, G., Poulter, N.R., Taddei, S., Unger, T., Volpe, M., Waeber, B., Zannad, F.: Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Press 14 (2005) 196–209

    CAS  PubMed  Google Scholar 

  204. Schmidt-Ott, K.M., Kagiyama, S., Phillips, M.I.: The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93 (2000) 65–77

    CAS  PubMed  Google Scholar 

  205. Lonn, E.: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep 4 (2002) 363–372

    PubMed  Google Scholar 

  206. Krum, H., Gilbert, R.E.: Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens 25 (2007) 25–35

    CAS  PubMed  Google Scholar 

  207. Higgins, J.P.: Can angiotensin-converting enzyme inhibitors reverse atherosclerosis? South Med J 96 (2003) 569–579

    PubMed  Google Scholar 

  208. Yasuda, N., Akazawa, H., Qin, Y., Zou, Y., Komuro, I.: A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol 377 (2008) 393–399

    CAS  PubMed  Google Scholar 

  209. O’Keefe, J.H., Wetzel, M., Moe, R.R., Bronsnahan, K., Lavie, C.J.: Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 37 (2001) 1–8

    PubMed  Google Scholar 

  210. Weir, M.R.: Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29 (2007) 1803–1824

    CAS  PubMed  Google Scholar 

  211. Ruilope, L.M., Redon, J., Schmieder, R.: Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag 3 (2007) 1–9

    CAS  PubMed  Google Scholar 

  212. Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Anderson, C.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547–1559

    CAS  PubMed  Google Scholar 

  213. Dagenais, G.R., Yusuf, S., Bourassa, M.G., Yi, Q., Bosch, J., Lonn, E.M., Kouz, S., Grover, J.: Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 104 (2001) 522–526

    CAS  PubMed  Google Scholar 

  214. Jukema, J.W., van der Hoorn, J.W.: Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin Pharmacother 5 (2004) 459–468

    CAS  PubMed  Google Scholar 

  215. Zanchetti, A., Hennig, M., Baurecht, H., Tang, R., Cuspidi, C., Carugo, S., Mancia, G.: Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 25 (2007) 2463–2470

    CAS  PubMed  Google Scholar 

  216. Zanchetti, A., Bond, M.G., Hennig, M., Neiss, A., Mancia, G., Dal Palu, C., Hansson, L., Magnani, B., Rahn, K.H., Reid, J.L., Rodicio, J., Safar, M., Eckes, L., Rizzini, P.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: ­principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 (2002) 2422–2427

    CAS  PubMed  Google Scholar 

  217. Mason, R.P., Marche, P., Hintze, T.H.: Novel vascular biology of third-generation l-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23 (2003) 2155–2163

    CAS  PubMed  Google Scholar 

  218. Mason, R.P.: Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am J Cardiol 88 (2001) 2M–6M

    CAS  PubMed  Google Scholar 

  219. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413–2446

    Google Scholar 

  220. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 153 (1993) 154–183

    Google Scholar 

  221. Psaty, B.M., Smith, N.L., Siscovick, D.S., Koepsell, T.D., Weiss, N.S., Heckbert, S.R., Lemaitre, R.N., Wagner, E.H., Furberg, C.D.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 (1997) 739–745

    CAS  PubMed  Google Scholar 

  222. Brown, M.J., Palmer, C.R., Castaigne, A., de Leeuw, P.W., Mancia, G., Rosenthal, T., Ruilope, L.M.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 (2000) 366–372

    CAS  PubMed  Google Scholar 

  223. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995–1003

    CAS  PubMed  Google Scholar 

  224. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981–2997

    Google Scholar 

  225. Psaty, B.M., Lumley, T., Furberg, C.D., Schellenbaum, G., Pahor, M., Alderman, M.H., Weiss, N.S.: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003) 2534–2544

    CAS  PubMed  Google Scholar 

  226. Wiysonge, C.S., Bradley, H., Mayosi, B.M., Maroney, R., Mbewu, A., Opie, L.H., Volmink, J.: Beta-blockers for hypertension. Cochrane Database Syst Rev (2007) CD002003

    Google Scholar 

  227. Staessen, J.A., Wang, J.G., Thijs, L.: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001) 1305–1315

    CAS  PubMed  Google Scholar 

  228. Staessen, J.A., Wang, J.G., Thijs, L.: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055–1076

    CAS  PubMed  Google Scholar 

  229. Turnbull, F.: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527–1535

    CAS  PubMed  Google Scholar 

  230. Verdecchia, P., Reboldi, G., Angeli, F., Gattobigio, R., Bentivoglio, M., Thijs, L., Staessen, J.A., Porcellati, C.: Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46 (2005) 386–392

    CAS  PubMed  Google Scholar 

  231. Law, M.R., Morris, J.K., Wald, N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338 (2009) b1665

    CAS  PubMed  Google Scholar 

  232. Migdalis, I.N., Gerolimou, B., Kozanidou, G., Hatzigakis, S.M., Karmaniolas, K.D.: Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. J Med 28 (1997) 371–380

    CAS  PubMed  Google Scholar 

  233. MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Mhurchu, C.N., Clark, T., Hart, H., Scott, J., White, H.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 36 (2000) 438–443

    CAS  PubMed  Google Scholar 

  234. Lonn, E., Yusuf, S., Dzavik, V., Doris, C., Yi, Q., Smith, S., Moore-Cox, A., Bosch, J., Riley, W., Teo, K.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 (2001) 919–925

    CAS  PubMed  Google Scholar 

  235. Hosomi, N., Mizushige, K., Ohyama, H., Takahashi, T., Kitadai, M., Hatanaka, Y., Matsuo, H., Kohno, M., Koziol, J.A.: Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 32 (2001) 1539–1545

    CAS  PubMed  Google Scholar 

  236. Asselbergs, F.W., van Roon, A.M., Hillege, H.L., de Jong, P.E., Gans, R.O., Smit, A.J., van Gilst, W.H.: Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 36 (2005) 649–653

    CAS  PubMed  Google Scholar 

  237. Wiklund, O., Hulthe, J., Wikstrand, J., Schmidt, C., Olofsson, S.O., Bondjers, G.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 33 (2002) 572–577

    CAS  PubMed  Google Scholar 

  238. Pitt, B., Byington, R.P., Furberg, C.D., Hunninghake, D.B., Mancini, G.B., Miller, M.E., Riley, W.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102 (2000) 1503–1510

    CAS  PubMed  Google Scholar 

  239. Borhani, N.O., Mercuri, M., Borhani, P.A., Buckalew, V.M., Canossa-Terris, M., Carr, A.A., Kappagoda, T., Rocco, M.V., Schnaper, H.W., Sowers, J.R., Bond, M.G.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 276 (1996) 785–791

    CAS  PubMed  Google Scholar 

  240. Zanchetti, A., Rosei, E.A., Palu, C., Leonetti, G., Magnani, B., Pessina, A.: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16 (1998) 1667–1676

    CAS  PubMed  Google Scholar 

  241. Simon, A., Gariepy, J., Moyse, D., Levenson, J.: Differential effects of nifedipine and ­co-amilozide on the progression of early carotid wall changes. Circulation 103 (2001) 2949–2954

    CAS  PubMed  Google Scholar 

  242. Boutouyrie, P., Bussy, C., Hayoz, D., Hengstler, J., Dartois, N., Laloux, B., Brunner, H., Laurent, S.: Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 101 (2000) 2601–2606

    CAS  PubMed  Google Scholar 

  243. Roman, M.J., Alderman, M.H., Pickering, T.G., Pini, R., Keating, J.O., Sealey, J.E., Devereux, R.B.: Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 11 (1998) 387–396

    CAS  PubMed  Google Scholar 

  244. Zanchetti, A., Crepaldi, G., Bond, M.G., Gallus, G., Veglia, F., Mancia, G., Ventura, A., Baggio, G., Sampieri, L., Rubba, P., Sperti, G., Magni, A.: Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial. Stroke 35 (2004) 2807–2812

    CAS  PubMed  Google Scholar 

  245. Ludwig, M., Stapff, M., Ribeiro, A., Fritschka, E., Tholl, U., Smith, R.D., Stumpe, K.O.: Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. Clin Ther 24 (2002) 1175–1193

    CAS  PubMed  Google Scholar 

  246. Hoogerbrugge, N., de Groot, E., de Heide, L.H., de Ridder, M.A., Birkenhageri, J.C., Stijnen, T., Jansen, H.: Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. Neth J Med 60 (2002) 354–361

    CAS  PubMed  Google Scholar 

  247. Koshiyama, H., Tanaka, S., Minamikawa, J.: Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. J Cardiovasc Pharmacol 33 (1999) 894–896

    CAS  PubMed  Google Scholar 

  248. Topouchian, J., Asmar, R., Sayegh, F., Rudnicki, A., Benetos, A., Bacri, A.M., Safar, M.E.: Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 30 (1999) 1056–1064

    CAS  PubMed  Google Scholar 

  249. Pontremoli, R., Viazzi, F., Ravera, M., Leoncini, G., Berruti, V., Bezante, G.P., Del Sette, M., Deferrari, G.: Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension. J Nephrol 14 (2001) 19–26

    CAS  PubMed  Google Scholar 

  250. Stanton, A.V., Chapman, J.N., Mayet, J., Sever, P.S., Poulter, N.R., Hughes, A.D., Thom, S.A.: Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin Sci (Lond) 101 (2001) 455–464

    CAS  Google Scholar 

  251. Terpstra, W.F., May, J.F., Smit, A.J., Graeff, P.A., Meyboom-de Jong, B., Crijns, H.J.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 22 (2004) 1309–1316

    CAS  PubMed  Google Scholar 

  252. Wang, J.-G.M.D.P., Staessen, J.A.M.D.P., Li, Y.M.D.P., Van Bortel, L.M.M.D.P., Nawrot, T.P., Fagard, R.M.D.P., Messerli, F.H.M.D., Safar, M.M.D.: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37 (2006) 1933–1940

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Anatomy, Pharmacology and Forensic Sciences, University of Turin, Via Pietro Giuria, 13, 10126, Torino, Italy

    Mario Eandi

Authors
  1. Mario Eandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Eandi .

Editor information

Editors and Affiliations

  1. Biomedical Technologies, Inc., Denver, Colorado, USA

    Jasjit S. Suri

  2. Planet Space, Inc., Chicago, Illinois, USA

    Chirinjeev Kathuria

  3. , Department of Electronics, Politecnico di Torino, Torino, Italy

    Filippo Molinari

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Eandi, M. (2011). Drug Therapy and Follow-Up. In: Suri, J., Kathuria, C., Molinari, F. (eds) Atherosclerosis Disease Management. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7222-4_19

Download citation

Publish with us

Policies and ethics

Search

Navigation